Precigen (PGEN) Stock
Biotechnology company developing genetic medicines and cell therapies. Here's the price, business snapshot, and what's worth knowing about Precigen in October 2026.
Precigen Inc (PGEN) is a clinical-stage biotechnology company focused on developing genetic medicines, cell and gene therapies and biologics. The business pursues a range of platform approaches designed to modify or harness the immune system and cellular machinery, with several preclinical and clinical programmes in its pipeline. With a market capitalisation of about $1.44 billion, Precigen is relatively small compared with large pharmaceutical companies and may be more sensitive to clinical, regulatory and financing events. Investors often watch trial readouts, regulatory milestones and partnership activity as potential catalysts. Biotech investing carries distinct risks: clinical outcomes can be binary, development timelines are long and additional capital may be required. This summary provides general, educational information and is not personalised investment advice. Consider whether the stock fits your risk tolerance and investment horizon, and consult a financial adviser for tailored guidance.
Precigen (PGEN) Stock Forecast
Analyst price target, next 12 months
$10.00
+17.1% vs today's $8.54
Price range over the last 12 months
Close to its 12-month high
Analysts covering Precigen have a consensus 12-month target of $10.00, above the current price of $8.54.
Analyst targets are opinions, not guarantees. Capital at risk. Data as of 5 Oct 2026.
Source: Analyst sentiment is provided by Refinitiv Ltd, a global leader in financial market data with over 40k business clients. Refinitiv Ltd is an independent third party to Nemo. This is not advice.
Sixth Month Growth Performance
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying Precigen's stock, believing it has the potential to reach $10.
Financial Health
Precigen is generating solid revenue and cash flow, with high profit margins indicating efficient operations.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Why You’ll Want to Watch This Stock
Pipeline Catalysts Ahead
Clinical readouts and regulatory milestones can move the share price; these events are worth watching, though outcomes are uncertain.
Platform Potential
The company’s gene and cell therapy platforms offer broad scientific reach, but technical hurdles and competition mean results are not guaranteed.
Partnerships Matter
Collaborations and licensing deals can de‑risk programmes or provide funding, yet terms and timings vary and may not remove development risk.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
